Abstract
AbstractA new fluorescent probe based on Eu (III) incorporated BSA‐AuNCs is developed for the selective sensing of sarcosine. Sarcosine is a simple non‐proteinogenic amino acid which is a clinical biomarker for prostate cancer. The non‐invasive sensing of a metabolite biomarker sarcosine for prostate cancer from urine sample was achieved through the developed Eu (III) incorporated BSA‐AuNCs probe. The developed sensor exhibited a good sensitivity and selectivity towards the metabolite sarcosine and observed no significant interference with other coexisting metabolites present in urine. The probe shows a very lower Limit of detection (LOD) of 0.177 mM and this probe can be developed for determining sarcosine on clinical basis. Considering its predominance and the pain associated invasive prostate cancer clinical examinations for the diagnosis, a non‐invasive diagnosis is of great need and significance.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
